Procarbazine, CCNU and Vincristine (PCV) Combination Chemotherapy for Brain Tumors

Publisher Website
Google Scholar
Abstract
Patients (2) with brain tumors were treated with a combination of procarbazine, CCNU (bis-2-chloroethyl-3-cyclohexyl-1-nitrosourea) and vincristine. Three of 8 patients (37.5%) with primary brain tumors responded to chemotherapy, with a mean duration of 9.3 mo. The mean survival of responders was 11.7 mo. vs. 3.6 mo. for nonresponders. Four patients with metastatic brain tumors were also treated with the same combination chemotherapy; only 1, suffering from a lymphoma of the brain, responded partially.